AllAnalyst Report
Morningstar•July 28, 2021
Morningstar•July 28, 2021Stryker Corporation: Stryker Sees Robust Recovery in Procedures, and We're Leaving Our Fair Value Estimate Unchanged
Summary
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, and spinal devices. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership p
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Boston Scientific CorporationApr 24, 2024 •
BSX
- Analyst Report: Thermo Fisher Scientific Inc.Apr 24, 2024 •
TMO
- Analyst Report: Quest Diagnostics IncorporatedApr 24, 2024 •
DGX
- EW: Lowering target price to $92.00Apr 24, 2024 •
EW
- GMED: What does Argus have to say about GMED?Apr 24, 2024 •
GMED
Analyst Profile
Debbie Wang
Senior Equity AnalystDebbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.